Smith & Nephew (NYSE:SNN) said yesterday that it launched the Intertan product assurance program centering on the performance Trigen Intertan intertrochanteric hip fracture nail.
The Trigen Intertan device is designed to use a Smith & Nephew proprietary integrated compression screw to reduce risk of implant failure and non-union, reduce postoperative pain and increase time to fracture union.
London-based Smith & Nephew’s IPA program is designed to mitigate expenses in the hip fracture market by reducing the overall reoperation rate. The company said if an implant fails to perform as expected, it will refund the cost of the implant to the facility for the 12 months that follow the patient’s procedure.
Pooled results from a meta-analysis published in Rheumatology and Orthopedic Medicine showed that the Intertan significantly reduced the the risk of implant-related failures by 81% and cut down on revision surgery by 65% when compared with single-screw nails.
“We feel that Trigen Intertan is the best hip fracture nail on the market, and we’re willing to back that up with a program that underscores our confidence,” VP and GM for trauma & extremities Craig Gaffin said in prepared remarks. “The clinical evidence supporting its efficacy is overwhelming. Better patient outcomes mean better outcomes for hospitals, and we are thrilled to pass along these savings to the US healthcare system.”
Shares of SNN were down -1.4% at $47.92 in mid-afternoon trading today.
